There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

• Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
• COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
• RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
• Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

• Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
• Disinfect frequently touched surfaces regularly, use sanitiser when outside.
• Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

One of the country's most popular condiment brands, Everest, is under tight FSSAI scrutiny after the food regulator ordered a temporary ban of sale of its hing (asafoetida) and a few masalas.

The Food Safety and Standards Authority of India (FSSAI) has prohibited the sale of compounded hing manufactured by Everest Food Products and Laljee Godhoo and Company after laboratory testing found samples that did not meet food safety standards.

The regulator has spotted compliance issues in three Everest spice blends. They include egg curry masala, chicken masala, and its widely sold garam masala.

To clarify, the three Everest masalas have not been banned permanently. They have been flagged for non-compliance, and the company has been asked to explain the violations and submit an action plan to resolve the said issues.

Why Is Everest's Hing Under Fire?

The action against hing came after a consumer complaint that prompted FSSAI to begin surveillance of major hing brands.

Samples were collected from Everest's facility in Mumbai and its manufacturing unit in Umbergaon, Gujarat, to be sent for laboratory testing.

According to FSSAI, its compounded hing samples tested contained only 0% to 3% alcohol-soluble extract, despite the prescribed minimum being 5%.

Compounded hing, which is not pure raw asafoetida, is a regulated food product made by blending raw hing with other ingredients like starches, flour, and gum Arabic. The required alcohol-soluble extract helps establish whether sufficient raw asafoetida is present in the final product.

FSSAI said the test results indicated that the products contained 30% to 40% less raw hing than required.

The regulator also found a separate problem in six varieties of raw hing tested at the Laljee Godhoo facility. Their starch content ranged between 15% and 32%, while the permitted maximum is 1%.

Also read: FSSAI Proposes Red Front-Of-Pack Warning Labels On Junk Food: How Will This Benefit Consumers’ Health?

What About Everest's Egg Curry, Chicken And Garam Masalas?

The regulator also detected non-compliance in Everest egg curry masala, chicken masala, and garam masala. However, unlike the hing products, these three spice blends have not been prohibited from sale.

The companies have been asked to explain the violations and submit action plans elaborating how they intend to comply with the food safety standards.

FSSAI has also advised the manufacturers to voluntarily recall substandard hing products already in the market.

Also read: US FDA Recalls Injectables Over Fiberglass, Steel Particles: See Affected Drugs

Motive Behind FSSAI's Action

FSSAI's action is a preventive food safety measure. The regulator said the manufacturers must address the violations and ensure their compounded hing meets the prescribed standards. The prohibition on the product will remain in place until compliance requirements are met.

For consumers, the episode also highlights the fact how food adulteration or substandard manufacturing is not always visible to the naked eye. A spice may look, smell and taste perfectly fine while still failing a major food safety standard.

Laboratory testing is therefore crucial for identifying problems like incorrect composition or inadequate levels of the ingredient in a product.

This comes at a time when FSSAI is tightening rules over food standards and labelling. Just days ago, the regulator proposed hexagonal red, front-of-pack warning labels for packaged junk foods that are high in sugar, salt or saturated fats. It told the Supreme Court that the aim is to make such information easier for consumers to understand.

The Food Safety and Standards Authority of India (FSSAI) has proposed putting prominent red, hexagonal warning labels on the front of packaged junk foods and beverages that are high in saturated fat, sugar or salt.

The proposal was submitted to the Supreme Court on August 28, marking a major update after years of debate over front-of-pack labelling.

The proposed labels would carry warnings like “HIGH FAT”, “HIGH SUGAR”, “HIGH SALT” or “HIGHLY SWEETENED BEVERAGE”, allowing consumers to identify products high in nutrients of concern without having to turn the packet around and decipher the nutrition panel.

Packaged Junk Foods To Carry Red Warning Labels Soon

At present, packaged foods generally provide nutritional information on the back or side of the package. For many shoppers, comparing the sugar, salt or fat content of several products can require some additional work of flipping and searching.

The proposed design is a red-coloured hexagonal symbol placed prominently on the front of the package. The first phase is expected to apply to products that are high in any two or more of the specified nutrients, according to the proposal reported by Reuters. The proposal also includes exemptions for certain foods that have single ingredients.

Also read: FSSAI Flags Food Firms For Misleading ‘100%’, ‘Energy Drink’, Immunity Claims

How Could The Red Label Help Consumers?

A prominent warning on the front of a packet could make it immediately obvious that a product contains high amounts of certain nutrients. This could be particularly useful when consumers are choosing between similar products.

It could also help parents make quicker decisions when buying packaged foods for children, who are increasingly being exposed to processed and ultra-processed foods.

The idea is not necessarily to tell consumers “never eat this”. Instead, the warning provides information before the purchase, allowing people to decide how frequently one should consume a type of packaged food.

A warning label, however, cannot compensate for an overall unhealthy diet, and consumers may still choose products carrying a warning. Its value lies in making important nutritional information harder to overlook.

The proposal comes after growing pressure from health activists and the Supreme Court, which has pushed the government to act on front-of-pack warnings amid concerns over rising obesity and chronic lifestyle diseases in India.

Also read: Centre Bans Cough & Cold Medicines For Children Under 4: What Parents Need To Know

The push for front-of-pack warnings is not coming only from health advocates. A recent LocalCircles survey of more than 83,000 consumers across 314 districts found strong support for prominent warnings on packaged foods and beverages high in sugar, salt or saturated fat.

80% of consumers said FSSAI should mandate such warnings, while another 11% wanted them specifically on ultra-processed foods. That means 91% supported front-of-pack warnings in some form, while only 4% felt existing format of nutrition information was more than enough.

Consumers also appeared to favour a warning that could be understood at a glance. 44% preferred a red warning symbol stating that a product was high in sugar, salt or saturated fat, while 27% chose traffic-light colour coding. Only 2% preferred a conventional black-and-white numerical nutrition panel.

But perhaps the most striking finding was what consumers said they would do with that information. 94% said a prominent warning would influence their buying decision.

Of these, 44% said they would avoid the product altogether, 26% would compare it with healthier alternatives and 24% would buy it less frequently. Only 6% said the warning would not affect their purchase.

Also read: ₹5 Crore Fake Medicine Racket Busted Near Bengaluru: Why Counterfeit Drugs In ICUs Are A Major Health Risk

Food Companies Have Opposed These Labels

The move has faced resistance from parts of the food and beverage industry. Companies and industry groups have argued that warning labels could be confusing or ineffective and that consumers should instead be encouraged to practise portion control.

Reuters reported that Coca-Cola India executive Mili Bhattacharya described it as “very simplistic” to believe that a symbol alone would significantly change people's diets.

Health advocates, however, have argued that consumers deserve clearer information about products that are high in nutrients linked to chronic disease.

Just a day before FSSAI proposed the red warning labels, Nestlé CEO Philipp Navratil said food manufacturers should be consulted as India develops its front-of-pack labelling rules.

According to Reuters, Navratil said the rules should be developed through a scientific approach and with input from food manufacturers.

The industry has previously pushed back against some proposals for warning labels, arguing that nutrition information needs to be presented in a way that gives consumers sufficient context rather than simply flagging individual nutrients.

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide), typically used to control Type 2 diabetes, to also reduce the risk of heart attack or stroke, the American drug maker said.

Mounjaro is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children aged 10 and older with Type 2 diabetes. It targets the GLP-1 protein and is also used for weight loss. In the US, the obesity version is sold under the brand name Zepbound.

Mounjaro: What Cardiovascular Risks Can It Reduce?

The FDA approved Mounjaro to lower the risk of major adverse cardiovascular events (MACE), including:

• Cardiovascular death
• Non-fatal heart attack
• Non-fatal stroke

Also read: UK Woman Dies After Sudden Abdominal Pain Following Increase In Her Mounjaro Dose

The approval applies to adults with Type 2 diabetes who are at high risk for these events.

“For people with Type 2 diabetes, heart disease is the leading cause of death, and Mounjaro – the number 1 most prescribed branded Type 2 diabetes medicine for adults in the US – now gives them a proven way to lower that risk, adding to the strong foundation it has already built in A1C and weight,” said Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health.

How Was Mounjaro Approved?

The FDA approval was based on results from a trial that showed Mounjaro outperformed Trulicity, Lilly’s older diabetes drug, in reducing the risk of heart attack and stroke in a large, head-to-head study.

The trial showed that Mounjaro reduced the risk of major adverse cardiovascular events by 8% more than Trulicity.

It was the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years.

The most commonly reported adverse events in SURPASS-CVOT for Mounjaro were gastrointestinal-related, generally mild to moderate in severity, and occurred primarily during the dose-escalation period.

What About Novo Nordisk’s Drugs?

Read More: GLP-1 Weight Loss Drugs Ozempic, Wegovy, Mounjaro Tied To Over 60 Reported Deaths In Australia

“Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with Type 2 diabetes at high risk for these events – in addition to its established A1C and weight loss benefits,” according to Lilly.

However, Danish rival Novo Nordisk secured FDA approval for its weight-loss drug Wegovy to lower heart risks in 2024 in overweight or obese adults without diabetes.

In 2025, the FDA also approved its older diabetes drug, Rybelsus, to reduce the risk of major adverse cardiovascular events in diabetic patients.

What Is Mounjaro?

Mounjaro is a brand name for tirzepatide, an injectable weekly treatment first approved by the US FDA for the control of Type 2 diabetes.

Unlike older weight-loss drugs that act on metabolism or suppress appetite as their primary mechanism, Mounjaro acts on two key hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These control the release of insulin and sensations of fullness.

By mimicking their action, Mounjaro decreases hunger and enhances blood sugar control — two key obstacles in successful weight maintenance.

How Does Mounjaro Work?

The key to Mounjaro’s success is tirzepatide, a dual-acting peptide that acts on receptors in the brain and stomach. When taken, it sets in motion a chain reaction of signals that tell the brain that you are full, helping reduce cravings and overeating.

Mounjaro also makes the body more responsive to insulin. In people with obesity, insulin resistance is frequent and can make weight loss more difficult. By enhancing insulin action, Mounjaro helps the body better control blood sugar and store less fat. In a sense, Mounjaro doesn’t simply allow you to eat less — it allows your body to use what you eat more efficiently.